Edwards Lifesciences (NYSE:EW) Issues Q4 2024 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.530-0.570 for the period, compared to the consensus earnings per share estimate of 0.620. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Edwards Lifesciences also updated its FY 2024 guidance to EPS.

Edwards Lifesciences Price Performance

EW stock traded down $0.30 during trading on Thursday, reaching $70.31. 6,738,042 shares of the company were exchanged, compared to its average volume of 4,577,810. The company has a market cap of $42.37 billion, a P/E ratio of 30.32, a PEG ratio of 2.83 and a beta of 1.13. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The stock’s 50 day moving average price is $68.04 and its 200 day moving average price is $78.71. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.66 earnings per share. As a group, analysts predict that Edwards Lifesciences will post 2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on EW shares. Oppenheimer reissued an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Barclays cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Finally, Morgan Stanley restated an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Fifteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $75.81.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,250 shares of company stock worth $1,099,238. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.